# mRNA-1010

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/mrna-1010
Canonical HTML page: https://getyourbrief.com/entity/mrna-1010

## Timeline

- **2026-Q4**: Anticipated PDUFA — Expected deadline for the FDA's final approval decision.
- **2026-02-18**: FDA U-Turn — FDA agrees to review the application after resolving the public dispute.
- **2026-02-18**: FDA U-Turn — Moderna confirms the FDA has resolved the dispute and will now consider the vaccine for approval.
- **2026-02-18**: Regulatory Reversal — FDA agrees to review the application after Moderna addresses concerns.
- **2026-02-18**: Regulatory U-Turn — The FDA officially agrees to consider the application after resolving the internal and public dispute.
- **2026-02-15**: Public Dispute — Moderna and administration officials engage in a public disagreement over the regulatory path forward.
- **2026-02-12**: Public Dispute — Reports emerge that career FDA scientists were overruled, leading to a public standoff between Moderna and the agency.
- **2026-02-10**: Political Controversy — Reports emerge that the vaccine chief overruled career scientists to block the shot.
- **2026-02-10**: Initial Rejection — Reports emerge that the FDA vaccine chief overruled scientists to reject Moderna's flu shot filing.
- **2026-02-05**: Initial Rejection — Trump administration vaccine chief refuses to review Moderna's mRNA flu shot application.
- **2026-01-10**: Refusal to File — FDA issues a shocking rejection of the application, sparking a public dispute.
- **2026-01**: Refusal to File — FDA issues an RTF citing deficiencies in the initial application.
- **2025-11-15**: Initial BLA Submission — Moderna submits its Biologics License Application for mRNA-1010.
- **2025-Q4**: BLA Submission — Moderna submits Biologics License Application for mRNA-1010.

## Recent coverage (5 stories, network-wide)

### FDA Reverses Course on Moderna mRNA Flu Shot Following Public Dispute
2026-02-19 09:53:59 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 13

The FDA has agreed to review Moderna’s mRNA-based influenza vaccine after a high-profile rejection by the Trump administration's vaccine chief. The reversal follows a public dispute where scientific staff were reportedly overruled, marking a significant shift for the first-of-its-kind vaccine candidate.
Full story: https://gethealthbrief.com/story/fda-moderna-flu-shot-reversal

### FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu Vaccine
2026-02-19 00:58:25 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 2

The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-vaccine-review

### FDA Reverses Stance on Moderna’s mRNA Flu Shot, Clearing Path for Review
2026-02-18 21:43:09 · Sector: finance · Sentiment: Positive · Impact: 7/10 · Sources: 3

The U.S. Food and Drug Administration has unexpectedly reversed its previous position, agreeing to review Moderna’s mRNA-based influenza vaccine candidate. This regulatory pivot marks a critical victory for Moderna as it seeks to diversify its portfolio beyond COVID-19 and challenge the traditional seasonal flu market.
Full story: https://getfinancebrief.com/story/fda-reversal-moderna-mrna-flu-shot-review

### FDA Reverses Course on Moderna mRNA Flu Shot After Controversial Rejection
2026-02-18 18:57:55 · Sector: finance · Sentiment: Positive · Impact: 8/10 · Sources: 6

The U.S. Food and Drug Administration has agreed to review Moderna’s experimental mRNA flu vaccine, reversing a previous decision that sparked a public dispute. The initial rejection, which reportedly saw political appointees overrule career scientists, had briefly cast doubt on the regulatory path for the company's post-COVID pipeline.
Full story: https://getfinancebrief.com/story/fda-moderna-flu-shot-reversal

### FDA Reverses Course on Moderna mRNA Flu Shot After Political Dispute
2026-02-18 18:51:48 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 6

Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.
Full story: https://getbiobrief.com/story/fda-reverses-moderna-flu-shot-review

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.